BAMCO Inc
PCRX icon

BAMCO Inc’s Pacira BioSciences PCRX Stock Holding History

BAMCO Inc’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-72,334
Closed -$3.45M – 329
2017
Q2 		$3.45M Buy
72,334
+23,200
+47% +$1.08M 0.02% 246
2017
Q1 		$2.24M Buy
49,134
+24,879
+103% +$1.08M 0.01% 255
2016
Q4 		$783K Buy
24,255
+2,334
+11% +$77.9K ﹤0.01% 294
2016
Q3 		$750K Sell
21,921
-34,430
-61% -$1.35M ﹤0.01% 283
2016
Q2 		$1.9M Buy
56,351
+40,140
+248% +$1.97M 0.01% 243
2016
Q1 		$859K Buy
16,211
+3,288
+25% +$192K ﹤0.01% 259
2015
Q4 		$992K Buy
12,923
+6,023
+87% +$341K ﹤0.01% 276
2015
Q3 		$284K Buy
+6,900
New +$423K ﹤0.01% 333
2015
Q2 		– Sell
-82,380
Closed -$7.32M – 359
2015
Q1 		$7.32M Buy
82,380
+15,292
+23% +$1.55M 0.03% 251
2014
Q4 		$5.95M Buy
67,088
+4,949
+8% +$468K 0.02% 261
2014
Q3 		$6.02M Sell
62,139
-92,254
-60% -$8.97M 0.02% 260
2014
Q2 		$14.2M Buy
154,393
+137,293
+803% +$10.5M 0.06% 222
2014
Q1 		$1.2M Buy
17,100
+10,605
+163% +$721K ﹤0.01% 303
2013
Q4 		$373K Buy
+6,495
New +$342K ﹤0.01% 315

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
PC
PointState Capital New York $7.82B AUM 43.51% 1-Year Est. Return

BAMCO Inc's PCRX Position: Q3 2017 in Review

BAMCO Inc sold out of Pacira BioSciences (PCRX) in Q3 2017, closing a stake of 72,334 shares — an estimated $3.45M sold.

BAMCO Inc first reported a position in PCRX in Q4 2013 and held it in 14 quarters. The position peaked at $14.2M in Q2 2014. 180 funds tracked by Wall St. Rank hold PCRX as of Q3 2017.

  • BAMCO Inc reported no remaining Pacira BioSciences position as of Q3 2017 after selling out during the quarter.
  • BAMCO Inc sold 72,334 Pacira BioSciences shares in Q3 2017, an estimated $3.45M.
  • BAMCO Inc first reported a position in Pacira BioSciences in Q4 2013 and held it in 14 quarters.
  • BAMCO Inc's Pacira BioSciences position peaked at $14.2M in Q2 2014.
  • 180 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2017.

Based on BAMCO Inc's 13F filing for Q3 2017, filed 15 Nov 2017.